Communiqués Acrivon Therapeutics, Inc.

Actions

ACRV

US0048901096

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 21:59:53 30/09/2026			Varia. 5j.	Varia. 1 janv.
2,041 ^USD	-1,88%		+0,73%	-13,90%

31/08	Acrivon Therapeutics, Inc. annonce la nomination de Michaela Levin au poste de Chief Business Officer, à compter du 31 août 2026	CI
12/08	Acrivon Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

02/09	Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference	GL
31/08	Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer	GL
12/08	Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts	GL
05/08	Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study	GL
21/07	Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference	GL
21/05	Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit	GL
15/05	Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	GL
13/05	Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts	GL
17/04	Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities	GL
15/04	Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	GL
19/03	Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights	GL
17/03	Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors	GL
03/03	Acrivon Therapeutics : Cowen Health Care Conference Webcast Slide Deck (18e99f)	PU
27/02	Acrivon Therapeutics : Presentation (1051ec)	PU
24/02	Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference	GL
24/02	Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference	AQ
23/02	Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress	GL
18/02	Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory	GL
18/02	Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory	AQ
23/01	Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress	GL
09/01	Acrivon Therapeutics : Presentation (8ea1462c a9cb 4560 a201 767eaadb1818)	PU
08/01	Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11	GL
08/01	Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11	AQ
06/01	Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast	GL
06/01	Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast	AQ